Close

Valeant Pharma (VRX) Talks to Sell Salix to Takeda for $10B Have Broken Down - DJ

November 30, 2016 10:02 AM EST

(Updated - November 30, 2016 10:05 AM EST)

Talks between Valeant Pharma (NYSE: VRX) and Takeda regarding a $10 billion deal for Salix have broken down, according to Dow Jones. The report said talks failed due to disagreements over price. Valeant now plans to focus on building the stomach-drug business.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Hot M&A, Mergers and Acquisitions, Rumors, Trader Talk